FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311585162> ?p ?o ?g. }

• W4311585162 abstract "To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2. In order to maximize the therapeutic effectiveness of such neutralizing antibodies, Fc engineering to modulate effector functions and to extend half-life is desirable. However, it is critical that Fc engineering does not negatively impact the developability properties of the antibodies, as these properties play a key role in ensuring rapid development, successful manufacturing, and improved overall chances of clinical success. In this study, we describe the biophysical characterization of a panel of Fc engineered (“TM-YTE”) SARS-CoV-2 neutralizing antibodies, the same Fc modifications as those found in AstraZeneca’s Evusheld (AZD7442; tixagevimab and cilgavimab), in which the TM modification (L234F/L235E/P331S) reduce binding to FcγR and C1q and the YTE modification (M252Y/S254T/T256E) extends serum half-life. We have previously shown that combining both the TM and YTE Fc modifications can reduce the thermal stability of the CH2 domain and possibly lead to developability challenges. Here we show, using a diverse panel of TM-YTE SARS-CoV-2 neutralizing antibodies, that despite lowering the thermal stability of the Fc CH2 domain, the TM-YTE platform does not have any inherent developability liabilities and shows an in vivo pharmacokinetic profile in human FcRn transgenic mice similar to the well-characterized YTE platform. The TM-YTE is therefore a developable, effector function reduced, half-life extended antibody platform." @default.
• W4311585162 created "2022-12-27" @default.
• W4311585162 creator A5000759391 @default.
• W4311585162 creator A5003934427 @default.
• W4311585162 creator A5011798928 @default.
• W4311585162 creator A5013048281 @default.
• W4311585162 creator A5018504567 @default.
• W4311585162 creator A5030604404 @default.
• W4311585162 creator A5032863821 @default.
• W4311585162 creator A5036949718 @default.
• W4311585162 creator A5038399654 @default.
• W4311585162 creator A5041720748 @default.
• W4311585162 creator A5042756464 @default.
• W4311585162 creator A5043224453 @default.
• W4311585162 creator A5044999448 @default.
• W4311585162 creator A5047038987 @default.
• W4311585162 creator A5053780153 @default.
• W4311585162 creator A5062927782 @default.
• W4311585162 creator A5063416119 @default.
• W4311585162 creator A5064802426 @default.
• W4311585162 creator A5066497879 @default.
• W4311585162 creator A5066932406 @default.
• W4311585162 creator A5067536254 @default.
• W4311585162 creator A5072163804 @default.
• W4311585162 creator A5074875947 @default.
• W4311585162 creator A5076842079 @default.
• W4311585162 creator A5079936607 @default.
• W4311585162 creator A5081967303 @default.
• W4311585162 creator A5082836130 @default.
• W4311585162 creator A5084053130 @default.
• W4311585162 creator A5087494835 @default.
• W4311585162 creator A5088256361 @default.
• W4311585162 creator A5088292851 @default.
• W4311585162 creator A5088889060 @default.
• W4311585162 date "2022-12-08" @default.
• W4311585162 modified "2023-09-27" @default.
• W4311585162 title "Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies" @default.
• W4311585162 cites W1595328377 @default.
• W4311585162 cites W1855086894 @default.
• W4311585162 cites W1906539852 @default.
• W4311585162 cites W1967455529 @default.
• W4311585162 cites W1969824500 @default.
• W4311585162 cites W1979162895 @default.
• W4311585162 cites W1995923662 @default.
• W4311585162 cites W1996045402 @default.
• W4311585162 cites W2002149424 @default.
• W4311585162 cites W2003326194 @default.
• W4311585162 cites W2017344199 @default.
• W4311585162 cites W2021160162 @default.
• W4311585162 cites W2028884049 @default.
• W4311585162 cites W2034515273 @default.
• W4311585162 cites W2036879738 @default.
• W4311585162 cites W2037840717 @default.
• W4311585162 cites W2039870425 @default.
• W4311585162 cites W2051724555 @default.
• W4311585162 cites W2071425823 @default.
• W4311585162 cites W2072081310 @default.
• W4311585162 cites W2078111332 @default.
• W4311585162 cites W2096960896 @default.
• W4311585162 cites W2115916264 @default.
• W4311585162 cites W2136782733 @default.
• W4311585162 cites W2137463204 @default.
• W4311585162 cites W2143562636 @default.
• W4311585162 cites W2148090354 @default.
• W4311585162 cites W2160374669 @default.
• W4311585162 cites W2170179543 @default.
• W4311585162 cites W2342299171 @default.
• W4311585162 cites W2517025561 @default.
• W4311585162 cites W2519035269 @default.
• W4311585162 cites W2566127747 @default.
• W4311585162 cites W2571209437 @default.
• W4311585162 cites W2578029714 @default.
• W4311585162 cites W2578585563 @default.
• W4311585162 cites W2606721249 @default.
• W4311585162 cites W2776027284 @default.
• W4311585162 cites W2810124926 @default.
• W4311585162 cites W2811304917 @default.
• W4311585162 cites W2904971004 @default.
• W4311585162 cites W2905282967 @default.
• W4311585162 cites W2911553020 @default.
• W4311585162 cites W2915355467 @default.
• W4311585162 cites W2947275699 @default.
• W4311585162 cites W2969038446 @default.
• W4311585162 cites W2988983475 @default.
• W4311585162 cites W3014709736 @default.
• W4311585162 cites W3033249816 @default.
• W4311585162 cites W3046480764 @default.
• W4311585162 cites W3154849380 @default.
• W4311585162 cites W4206984346 @default.
• W4311585162 cites W4226525051 @default.
• W4311585162 cites W4281665851 @default.
• W4311585162 cites W4296025810 @default.
• W4311585162 doi "https://doi.org/10.1080/19420862.2022.2152526" @default.
• W4311585162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36476037" @default.
• W4311585162 hasPublicationYear "2022" @default.
• W4311585162 type Work @default.
• W4311585162 citedByCount "3" @default.
• W4311585162 countsByYear W43115851622023 @default.
• W4311585162 crossrefType "journal-article" @default.
• W4311585162 hasAuthorship W4311585162A5000759391 @default.

• next